With Academic Funding, GSK Looks to Zap Life Into Electroceuticals
This article was originally published in The Gray Sheet
Executive Summary
By seeding exploratory lab work across several biomedical and engineering disciplines, pharma giant GlaxoSmithKline wants to understand how neural signals regulate diseases and eventually to design devices that can alter signals and provide therapeutic benefit.
You may also be interested in...
Small Boost In Proposed NIH Budget Could Help Fund Electroceuticals Project
The National Institutes of Health would see only a slight, less than 1%, increase over 2014 in its fiscal year 2015 budget under the president’s spending plan, but part of the increase could advance so-called electroceuticals research, NIH director Francis Collins explained.
Small Boost In Proposed NIH Budget Could Help Fund Electroceuticals Project
The National Institutes of Health would see only a slight, less than one percent, increase over 2014 in its fiscal year 2015 budget under the president’s spending plan, but part of the increase could advance so-called electroceuticals research, NIH Director Francis Collins explained.
GSK Ventures Into Device World With Bioelectronic Investment
The British pharmaceutical maker has financed a new venture capital fund to create a presence in emerging bioelectronic technology and to help jumpstart the fledgling industry because it believes that the science has reached a transition point.